Raising awareness of neuroendocrine cancers around the world

Afinitor and Pancreatic NET Patients in the EU

Pancreatic NET patients in the EU with unresectable or metastatic tumors may soon have the first mTOR inhibitor drug to be approved for pNET patients. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has backed Novartis’ Afinitor. The European Commission is expected to follow the CHMP recommendation and will deliver its final decision within the next three months.

Read More